Simona E Carbone, Michelle P Papadimitriou and Darren J Kelly, discuss why GPR68 has been considered an attractive target for cancer therapy – albeit difficult to drug – and highlight its exciting potential in the development of drugs to treat a range of inflammatory and fibrotic diseases. GPR68, or OGR1, is an orphan, acid-sensing G-protein coupled receptor […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!